Prothena (PRTA) said Thursday the phase 2b study conducted by partner Roche evaluating prasinezumab for the treatment of early-stage Parkinson's disease missed its primary endpoint.
However, the study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints, the company said.
The results will therefore be used to inform future clinical development of the drug candidate as a potential disease-modifying treatment for patients with Parkinson's disease.
Meanwhile, Roche is further evaluating the data and will work with health authorities to determine the next steps.
Prothena's share price fell over 6% in recent premarket activity Thursday.
Price: 11.21, Change: -0.74, Percent Change: -6.19
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.